Initial results of a phase i dose-escalation trial of concurrent and maintenance erlotinib and reirradiation for recurrent and new primary head-and-neck cancer

International Journal of Radiation Oncology Biology Physics

Volumn 78, Issue 4, 2010, Pages 1020-1025

  Rusthoven, Kyle E ^a   Feigenberg, Steven J ^b   Raben, David ^a   Kane, Madeleine ^a   Song, John I ^a   Nicolaou, Nicos ^b   Mehra, Ranee ^b   Burtness, Barbara ^b   Ridge, John ^b   Swing, Robyn ^a   Lango, Miriam ^b   Cohen, Roger ^b   Jimeno, Antonio ^a   Chen, Changhu ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

Erlotinib; Head and neck cancer; Recurrent; Reirradiation

Indexed keywords

ACUTE TOXICITY; DISEASE PROGRESSION; DOSE LIMITING TOXICITY; ERLOTINIB; HEAD-AND-NECK CANCER; OSTEORADIONECROSIS; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; PHASE I; RADIATION THERAPY; RECURRENT; REIRRADIATION;

MAINTENANCE; RADIOTHERAPY;

TOXICITY;

ERLOTINIB; ANTINEOPLASTIC AGENT; CETUXIMAB; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ADULT; ARTICLE; ASPIRATION; ASPIRATION PNEUMONIA; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL EVALUATION; CLINICAL TRIAL; COHORT ANALYSIS; CONJUNCTIVITIS; CONTROLLED STUDY; DEHYDRATION; DERMATITIS; DIARRHEA; DRUG DOSE ESCALATION; DYSPHAGIA; FATIGUE; FEMALE; FOLLOW UP; GASTROTOMY; HEAD AND NECK CANCER; HUMAN; INTERSTITIAL LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SIDE EFFECT; WEIGHT REDUCTION; XEROSTOMIA; AGED; CARCINOMA, SQUAMOUS CELL; DRUG ADMINISTRATION; FEASIBILITY STUDY; GASTROSTOMY; HEAD AND NECK NEOPLASMS; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; NEOPLASM RECURRENCE, LOCAL; PROCEDURES; RADIATION DOSE; RETREATMENT; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; GASTROSTOMY; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RADIOTHERAPY DOSAGE; RETREATMENT; TREATMENT OUTCOME; ANTIBODIES, MONOCLONAL, HUMANIZED;

EID: 77958472983     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.09.003     Document Type: Article

References (23)

1. A.A. Forastiere, T. Leong, and E. Rowinsky Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393 J Clin Oncol 19 2003 1088 1095
2. M.K. Gibson, Y. Li, and B. Murphy Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): An intergroup trial of the Eastern Cooperative Oncology Group J Clin Oncol 23 2005 3562 3567
3. J.B. Vermorken, R. Mesia, and F. Rivera Platinum-based chemotherapy plus cetuximab in head and neck cancer N Engl J Med 359 2008 1116 1127
4. J.K. Salama, E.E. Vokes, and S.J. Chmura Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma Int J Radiat Oncol Biol Phys 64 2006 382 391
5. N.M. Kramer, E.M. Horwitz, and J. Cheng Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studies Head Neck 27 2005 406 414
6. C.J. Langer, J. Harris, and E.M. Horwitz Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: Results of Radiation Therapy Oncology Group Protocol 9911 J Clin Oncol 25 2007 4800 4805
7. S.A. Spencer, J. Harris, and R.H. Wheeler Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck Head Neck 30 2008 281 288
8. F. Janot, D. de Raucourt, and E. Benhamou Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma J Clin Oncol 26 2008 5518 5523
9. J.A. Bonner, P.M. Harari, and J. Giralt Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck N Engl J Med 354 2006 567 578
10. B.H. O'Neil, R. Allen, and D.R. Spigel High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history J Clin Oncol 25 2007 3644 3648
11. C.H. Chung, B. Mirakhur, and E. Chan Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose N Engl J Med 358 2008 1109 1117
12. F.A. Shepherd, J. Rodrigues Pereira, and T. Ciuleanu Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2005 123 132
13. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Available from: URL: http://ctep.info.nih.gov/protocolDevelopment/electronic-applications/ docs/ctcaev3.pdf. accessed May 6, 2009.
14. RTOG toxicity criteria. RTOG Web site. Available from: URL: http://www.rtog.org/members/toxicity/late.html. Accessed May 6, 2009.
15. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
16. RTOG protocol 0421. RTOG Web site. Available from: URL: http://www.rtog.org/members/protocols/0421/0421.pdf.
17. W.K. Hong, R.H. Bromer, and D.A. Amato Patterns of relapse in locally advanced head and neck cancer patients who achieved complete remission after combined modality therapy Cancer 56 1985 1242 1245
18. V. Paleri, and C.G. Kelly Re-irradiation with concurrent chemotherapy in recurrent head and neck cancer: a decision analysis model based on a systematic review Clin Otolaryngol 33 2008 331 337
19. K.K. Fu, T.F. Pajak, and A. Trotti A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003 Int J Radiat Oncol Biol Phys 48 2000 7 16
20. R. De Crevoisier, J. Bourhis, and C. Domenge Full-dose reirradiation for unresectable head and neck carcinoma: Experience at the Gustave-Roussy Institute in a series of 169 patients J Clin Oncol 16 1998 3556 3562
21. T.Y. Seiwert, D.J. Haraf, and E.E. Cohen Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer J Clin Oncol 26 2008 1732 1741
22. K.K. Ang, G.L. Jiang, and Y. Feng Extent and kinetics of recovery of occult spinal cord injury Int J Radiat Oncol Biol Phys 50 2001 1013 1020
23. E.P. Sulman, D.L. Schwartz, and T.T. Le IMRT reirradiation of head and neck cancer-disease control and morbidity outcomes Int J Radiat Oncol Biol Phys 73 2009 399 409